Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CASR | P41180 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5245493 | 1.00 | BCHE (0.66) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5273201 | 0.93 | BCHE (0.61) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5267369 | 0.92 | BCHE (0.60) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5268399 | 0.92 | SMN1; SMN2 (0.67) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5266725 | 0.90 | BCHE (0.59) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5274105 | 0.90 | MEN1 (0.67) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5270611 | 0.90 | BCHE (0.59) | BCHESMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL5274134 | 0.87 | MEN1 (0.60) | BCHEMEN1KMT2APOLBMAPK1 | |
| SCHEMBL7520551 | 0.87 | MEN1 (0.63) | BCHEMEN1KMT2APOLBMAPK1 | |
| SCHEMBL5271408 | 0.87 | MAOB (0.58) | BCHEMEN1KMT2APOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253932-A1 | Resolution of Racemic Organic Acids with (1S, 4S)-4[3,4-Dichlorophenyl]-1,2,3,4-Tetrahydro-N-Methyl-1-Naphthaloneamine | MATRIX LABORATORIES LTD (IN) | 2009-10-08 | — | — | US | disclosed |
| EP-1831132-A2 | RESOLUTION OF RACEMIC ORGANIC ACIDS WITH (1S, 4S)-4[3,4-DICHLOROPHENYL]-1,2,3,4- TETRAHYDRO-N-METHYL-1-NAPHTHALONEAMINE | Matrix Laboratories Ltd (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006013581-A2 | RESOLUTION OF RACEMIC ORGANIC ACIDS WITH (1S, 4S)-4[3,4-DICHLOROPHENYL]-1,2,3,4- TETRAHYDRO-N-METHYL-1-NAPHTHALONEAMINE | MATRIX LABORATORIES LTD (IN) | 2006-02-09 | — | — | WO | disclosed |
| US-6894190-B2 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-05-17 | — | — | US | disclosed |
| US-6653507-B2 | Useful intermediate compound of pharmaceuticals for urinary incontinence | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2002-10-03 | — | — | US | disclosed |
| EP-1074539-A2 | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253932-A1 | Resolution of Racemic Organic Acids with (1S, 4S)-4[3,4-Dichlorophenyl]-1,2,3,4-Tetrahydro-N-Methyl-1-Naphthaloneamine | HTR4, OXER1, CYP2S1 | BCHE 2776/4885SMN1; SMN2 3490/4885MEN1 1897/4885 |
| US-20020143212-A1 | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | ALDH1A2, ALDH7A1, ALDH18A1 | BCHE 2684/4885SMN1; SMN2 913/4885MEN1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.